ReviewOncotarget2010
Targeting tumors with salmonella Typhimurium- potential for therapy.
Review in Oncotarget, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Tumour-specific delivery of ω-conotoxin MVIIA via engineered Salmonella for safe anticancer therapy.Journal of advanced research · 2026Article
- Intratumoral microbiota: bidirectional modulation of tumor radiosensitivity.Frontiers in immunology · 2026Review
- Bioinspired functional materials for biomedical applications.Frontiers in bioengineering and biotechnology · 2026Review
- Current status and future perspectives of multi-modal bacteria-based cancer therapies.Clinical and translational medicine · 2025Review
- Beyond Tumor Borders: Intratumoral Microbiome Effects on Tumor Behavior and Therapeutic Responses.Immune network · 2024Review
- The oncolytic bacteria-mediated delivery system of CCDC25 nucleic acid drug inhibits neutrophil extracellular traps induced tumor metastasis.Journal of nanobiotechnology · 2024Article
- Constitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria.Cancers · 2023Article
- The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors.Nanomaterials (Basel, Switzerland) · 2021Review
- The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.Future microbiology · 2021Review
- Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-CancerFrontiers in immunology · 2021Article
- Strategies for developing and optimizing cancer vaccines.F1000Research · 2019Review
- Developing a Roadmap for Interventional Oncology.The oncologist · 2018Review
- Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
- Engineering of a rough auxotrophic mutantOncotarget · 2018Article
- Salmonella enterica Serovar Typhimurium Increases Functional PD-L1 Synergistically with Gamma Interferon in Intestinal Epithelial Cells via Salmonella Pathogenicity Island 2.Infection and immunity · 2018Article
- Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018Article
- Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment.Frontiers in oncology · 2018Article
- Cancer Immunotherapy: Priming the Host Immune Response with Live AttenuatedJournal of immunology research · 2018Review
- Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.Oncotarget · 2017Article
- 'Obligate' anaerobicOncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
When one considers the organism Salmonella enterica serotype Typhimurium (S. Typhimurium), one usually thinks of the Gram-negative enteric pathogen that causes the severe food borne illness, gastroentertitis. In this context, the idea of Salmonella being exploited as a cancer therapeutic seems pretty remote. However, there has been an escalating interest in the development of tumor-therapeutic bacteria for use in the treatment of a variety of cancers. This strategy takes advantage of the remarkable ability of certain bacteria to preferentially replicate and accumulate within tumors. In the case of S. Typhimurium, this organism infects and selectively grows within implanted tumors, achieving tumor/normal tissue ratios of approximately 1,000:1. Salmonella also has some attractive properties well suited for the design of a chemotherapeutic agent. In particular, this pathogen can easily be manipulated to carry foreign genes, and since this species is a facultative anaerobe, it is able to survival in both oxygenated and hypoxic conditions, implying this organism could colonize both small metastatic lesions as well as larger tumors. These observations are the impetus to a burgeoning field focused on the development of Salmonella as a clinically useful anti-cancer agent. We will discuss three cutting edge technologies employing Salmonella to target tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.